126 related articles for article (PubMed ID: 27486855)
1. Nutrient Starvation Sensitizes Human Ovarian Cancer SKOV3 Cells to BH3 Mimetic via Modulation of Mitochondrial Dynamics.
Wang S; Mao Y; Xi S; Wang X; Sun L
Anat Rec (Hoboken); 2017 Feb; 300(2):326-339. PubMed ID: 27486855
[TBL] [Abstract][Full Text] [Related]
2. ABT737 induces mitochondrial pathway apoptosis and mitophagy by regulating DRP1-dependent mitochondrial fission in human ovarian cancer cells.
Yu Y; Xu L; Qi L; Wang C; Xu N; Liu S; Li S; Tian H; Liu W; Xu Y; Li Z
Biomed Pharmacother; 2017 Dec; 96():22-29. PubMed ID: 28963947
[TBL] [Abstract][Full Text] [Related]
3. ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation.
Hou L; Wang R; Wei H; Li S; Liu L; Lu X; Yu H; Liu Z
Life Sci; 2019 Sep; 232():116561. PubMed ID: 31247208
[TBL] [Abstract][Full Text] [Related]
4. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
[TBL] [Abstract][Full Text] [Related]
5. Bcl2 inhibitor ABT737 reverses the Warburg effect via the Sirt3-HIF1α axis to promote oxidative stress-induced apoptosis in ovarian cancer cells.
Dong D; Dong Y; Fu J; Lu S; Yuan C; Xia M; Sun L
Life Sci; 2020 Aug; 255():117846. PubMed ID: 32470451
[TBL] [Abstract][Full Text] [Related]
6. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
8. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
9. ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics.
Fan Z; Yu H; Cui N; Kong X; Liu X; Chang Y; Wu Y; Sun L; Wang G
Exp Cell Res; 2015 Jul; 335(1):68-81. PubMed ID: 25936772
[TBL] [Abstract][Full Text] [Related]
10. BH3 mimetics activate multiple pro-autophagic pathways.
Malik SA; Orhon I; Morselli E; Criollo A; Shen S; Mariño G; BenYounes A; Bénit P; Rustin P; Maiuri MC; Kroemer G
Oncogene; 2011 Sep; 30(37):3918-29. PubMed ID: 21460857
[TBL] [Abstract][Full Text] [Related]
11. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
12. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin.
Geserick P; Wang J; Feoktistova M; Leverkus M
Cell Death Dis; 2014 Sep; 5(9):e1412. PubMed ID: 25210795
[TBL] [Abstract][Full Text] [Related]
13. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
16. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
18. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
Aranovich A; Liu Q; Collins T; Geng F; Dixit S; Leber B; Andrews DW
Mol Cell; 2012 Mar; 45(6):754-63. PubMed ID: 22464442
[TBL] [Abstract][Full Text] [Related]
19. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
20. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
